The Evolving Landscape of Behavioral Health Transactions: Insights from Industry Professionals
AGG Talks: Cross-Border Business Podcast - Episode 19: The Rise of Korean Investment in the Southeast U.S.
The Standard Formula Podcast | Insurers in Difficulty: Staying Compliant Under Solvency II
Navigating Facility Relocation: Legal and Practical Considerations — The Consumer Finance Podcast
Public M&A Day in Frankfurt
JONES DAY TALKS®: Corporate Venture Capital: Market Overview, Trends in Deal Terms, and Special Considerations
La Financiación de Proyectos de Infraestructura
PLI's inSecurities Podcast - Commissioner Uyeda on “the Perils of Regulation by Theory and Hypothesis”
The Standard Formula Podcast | Back to Basics: Exploring the Many Facets of the Solvency II Regime
JONES DAY TALKS®: Preparing for FRTB: What Banks Should Know
Global Capital Markets Update with Kroll
Exit Strategies for GOVCONs with Set Aside Contracts: 2021 Insights and Lessons Learned from Business Owners and Advisors
Venture Capital: Global State of the Market
Cameras Roll on Spicer and Miller Discussing 2016 Entertainment Trends and Looking Forward to 2017
Debt Financing Trends – Joe Price, Member, Corporate & Securities Practice
Wilson Sonsini’s inaugural Biotech Summit will address topics of critical importance to Biotech and Biopharmaceutical companies, including early and late-stage venture financing, partnering strategies, current and future AI...more
In November, we were delighted to once again host our annual European Health & Life Sciences Symposium in Paris. The event attracted a large number of healthcare professionals, investors and dealmakers to the Shangri-La Hotel...more
Encouraged by the relative strength of the dollar and improving financing conditions, US bidders are snapping up European assets - Transatlantic M&A was enjoying record-high activity before the war in Ukraine sparked...more
In this issue of the 2022 Technology and Life Sciences IPO Report, we present analysis related to 10 initial public offerings (IPOs), valued at over $75 million, completed by U.S.-based technology and life sciences companies...more
As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next? Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more
Dealmakers in almost every industry had an outstandingly busy 2021. With just a few exceptions, the M&A boom swept across the US economy with deal values, in particular, up significantly on 2020 totals. Nevertheless,...more
Following a year of healthy activity, M&A deals in the pipeline are set to sustain leveraged finance issuance in the pharmaceutical, medical and biotech sector in the months ahead - Lender appetite for exposure to the...more
It is now a year since the WHO declared an International Public Health Emergency after the first international case of a novel coronavirus infection was identified outside of China. We remain right in the middle of spiralling...more
COVID-19 has pushed healthcare systems around the world to the limit, but depending on the vertical, certain companies have been less affected than those in other sectors—and the availability of credit to battle the pandemic...more